Why and how have drug discovery strategies in pharma changed? What are the new mindsets?

被引：53

作者：

Mignani, Serge ^{[1
]}

Huber, Scot ^{[2
]}

Tomas, Helena

Rodrigues, Joao ^{[3
]}

Majoral, Jean-Pierre ^{[4
,5
]}

机构：

[1] Univ Paris 05, CNRS UMR 860, Lab Chim & Biochim Pharmacol & Toxicol, PRES Sorbonne Paris Cite, 45 Rue St Peres, F-75006 Paris, France

[2] SCYNEXIS Inc, POB 12878, Res Triangle Pk, NC 27709 USA

[3] Univ Madeira, CQM, MMRG, Campus Univ Penteada, P-9000390 Funchal, Portugal

[4] CNRS, Lab Chim Coordinat, 205 Route Narbonne,BP 44099, F-31077 Toulouse 4, France

[5] Univ Toulouse, UPS, INPT, F-31077 Toulouse 4, France

来源：

DRUG DISCOVERY TODAY | 2016年 / 21卷 / 02期

关键词：

CHEMICAL BEAUTY; OPEN INNOVATION; 1ST-IN-CLASS; CHALLENGES; REVOLUTION; IMPACT; SPACE;

D O I：

10.1016/j.drudis.2015.09.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the pharmaceutical industry the long-term challenge of drug innovation is the key phrase throughout R&D that refers to increasing the output of original drug candidate molecules. To increase R&D productivity, implementation of new and strategic R&D orientations to develop new approaches or systems to identify hits and leads efficiently has taken place and enabled all scientists working in the drug discovery domain to develop innovative medicines for the 21st century.

引用

页码：239 / 249

页数：11

共 50 条

[11] How and why AIDS changed drug policy in Switzerland
Bertino Somaini
Peter Grob
Journal of Public Health Policy, 2012, 33 : 317 - 324
[12] How and why AIDS changed drug policy in Switzerland
Somaini, Bertino
Grob, Peter
JOURNAL OF PUBLIC HEALTH POLICY, 2012, 33 (03) : 317 - 324
[13] THE 2008 ACCC MERGER GUIDELINES: HOW AND WHY HAVE THEY CHANGED?
King, Stephen P.
UNIVERSITY OF NEW SOUTH WALES LAW JOURNAL, 2009, 32 (01): : 263 - 274
[14] The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes
Gribkoff, Valentin K.
Kaczmarek, Leonard K.
NEUROPHARMACOLOGY, 2017, 120 : 11 - 19
[15] Promising drug discovery strategies for sirtuin modulators: what lessons have we learnt?
Garg, Geetika
Singh, Abhishek Kumar
Singh, Sandeep
Rizvi, Syed Ibrahim
EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (08) : 915 - 927
[16] The Who, What, and Why of Drug Discovery and Development
Hogan, Glenn
Tangney, Mark
TRENDS IN PHARMACOLOGICAL SCIENCES, 2018, 39 (10) : 848 - 852
[17] Academia-pharma partnerships for novel drug discovery: essential or nice to have?
Palmer, Michelle
Chaguturu, Rathnam
EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (06) : 537 - 540
[18] Leadership mindsets: Why new managers fail and what to do about it
Crane, Bret
BUSINESS HORIZONS, 2022, 65 (04) : 447 - 455
[19] Transporters and drug discovery: Why, when, and how
Kim, Richard B.
MOLECULAR PHARMACEUTICS, 2006, 3 (01) : 26 - 32
[20] How We Teach Science: What Changed, and Why it Matters
Lufkin, Patrick
TECHNICAL COMMUNICATION, 2020, 67 (01) : 121 - 121

← 1 2 3 4 5 →